Based on our findings we draw the overall conclusion that neoadjuvant letrozole treatment renders more than half of postmenopausal ER+/PgR+ mastectomy candidates eligible for lumpectomy within only 4 months and that prolonged treatment for up to 8 months can result in further tumor volume reduction and, thus, provide incremental benefit to patients. The gene discussed is ESR1; the disease is neoplasm.